TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 12,050 shares, a growth of 52.4% from the July 15th total of 7,908 shares. Based on an average daily trading volume, of 3,956 shares, the days-to-cover ratio is currently 3.0 days.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in TLSIW. Fort Baker Capital Management LP acquired a new stake in TriSalus Life Sciences during the fourth quarter worth about $44,000. Aristeia Capital L.L.C. bought a new stake in shares of TriSalus Life Sciences in the 4th quarter worth approximately $43,000. Citadel Advisors LLC grew its holdings in shares of TriSalus Life Sciences by 439.0% during the 3rd quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock worth $199,000 after purchasing an additional 103,336 shares in the last quarter. Finally, Cerity Partners LLC acquired a new stake in shares of TriSalus Life Sciences during the 4th quarter worth approximately $1,374,000.
TriSalus Life Sciences Stock Performance
NASDAQ:TLSIW traded up $0.44 during midday trading on Tuesday, reaching $1.00. The stock had a trading volume of 220 shares, compared to its average volume of 5,207. TriSalus Life Sciences has a 1-year low of $0.44 and a 1-year high of $2.29. The firm’s fifty day simple moving average is $0.82 and its 200-day simple moving average is $1.00.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.
Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.
Further Reading
- Five stocks we like better than TriSalus Life Sciences
- Fabrinet’s Sell-Off May Prove It Is One of AI’s Most Misunderstood Stocks
- Orbiting Wealth: Institutions Load Up SpaceX
- Uncle Sam’s Chip Trick: How the Government Built a Silicon Moat
- 3 Infrastructure Stocks Built Around the Backbone of the Economy
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
